Autonomix Medical (AMIX) EBITDA (2022 - 2025)

Autonomix Medical (AMIX) has 4 years of EBITDA data on file, last reported at -$3.3 million in Q4 2025.

• On a quarterly basis, EBITDA fell 21.7% year-over-year to -$3.3 million in Q4 2025; TTM through Dec 2025 was -$17.6 million, a 63.23% decrease from a year earlier, with the FY2025 full-year figure at -$11.6 million, up 3.67% from the prior year.
• EBITDA for Q4 2025 stood at -$3.3 million, up from -$7.5 million in the prior quarter.
• Over the last five years, EBITDA for AMIX reached as high as -$544000.0 in Q4 2022 and fell as low as -$7.5 million in Q3 2025.
• Historically, EBITDA has averaged -$3.0 million across 4 years, with a median of -$2.8 million in 2024.
• Across the five-year window, EBITDA sank 437.5% in 2023 and jumped 51.27% in 2024, its largest moves.
• Year by year, EBITDA stood at -$544000.0 in 2022, then sank by 437.5% to -$2.9 million in 2023, then climbed by 6.05% to -$2.7 million in 2024, then decreased by 21.7% to -$3.3 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$3.3 million in Q4 2025, -$7.5 million in Q3 2025, and -$3.4 million in Q2 2025.